These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37788646)

  • 1. A prospective comparison study of subcutaneous and intramuscular testosterone injections in transgender male adolescents.
    Baines HK; Connelly KJ
    J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1028-1036. PubMed ID: 37788646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family Building Perspectives of Assigned Female at Birth Transgender and Gender Diverse Adolescents Seeking Testosterone Gender-Affirming Hormone Therapy.
    Garborcauskas G; McCabe E; Boskey ER; Grimstad FW
    LGBT Health; 2022 Oct; 9(7):463-470. PubMed ID: 35802494
    [No Abstract]   [Full Text] [Related]  

  • 3. A European Network for the Investigation of Gender Incongruence in adolescents.
    Boogers LS; Wiepjes CM; Staphorsius AS; Klink DT; Ciancia S; Romani A; Stolk THR; van den Boogaard E; Steensma TD; de Vries ALC; van Trotsenburg ASP; den Heijer M; Fisher AD; Cools M; Hannema SE
    J Sex Med; 2024 Mar; 21(4):350-356. PubMed ID: 38427555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Assigned at Birth Ratio Among Transgender and Gender Diverse Adolescents in the United States.
    Turban JL; Dolotina B; King D; Keuroghlian AS
    Pediatrics; 2022 Sep; 150(3):. PubMed ID: 35918512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mental Health Status of Cisgender and Gender-Diverse Secondary School Students in China.
    Wang Y; Yu H; Yang Y; Drescher J; Li R; Yin W; Yu R; Wang S; Deng W; Jia Q; Zucker KJ; Chen R
    JAMA Netw Open; 2020 Oct; 3(10):e2022796. PubMed ID: 33107922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients.
    Spratt DI; Stewart II; Savage C; Craig W; Spack NP; Chandler DW; Spratt LV; Eimicke T; Olshan JS
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2349-2355. PubMed ID: 28379417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study.
    Wilson DM; Kiang TKL; Ensom MHH
    Am J Health Syst Pharm; 2018 Mar; 75(6):351-358. PubMed ID: 29367424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Subcutaneous and Intramuscular Estradiol Regimens as Part of Gender-Affirming Hormone Therapy.
    Herndon JS; Maheshwari AK; Nippoldt TB; Carlson SJ; Davidge-Pitts CJ; Chang AY
    Endocr Pract; 2023 May; 29(5):356-361. PubMed ID: 36868378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgender Dependent Adolescents in the U.S. Military Health Care System: Demographics, Treatments Sought, and Health Care Service Utilization.
    Van Donge N; Schvey NA; Roberts TA; Klein DA
    Mil Med; 2019 May; 184(5-6):e447-e454. PubMed ID: 30325452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Testosterone: An Effective Delivery Mechanism for Masculinizing Young Transgender Men.
    Olson J; Schrager SM; Clark LF; Dunlap SL; Belzer M
    LGBT Health; 2014 Sep; 1(3):165-7. PubMed ID: 26789709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Quality of Life of Transgender and Gender-Diverse Children and Adolescents in Melbourne, Australia, 2017-2020.
    Engel L; Majmudar I; Mihalopoulos C; Tollit MA; Pang KC
    JAMA Netw Open; 2023 Feb; 6(2):e2254292. PubMed ID: 36729456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial.
    Nolan BJ; Zwickl S; Locke P; Zajac JD; Cheung AS
    JAMA Netw Open; 2023 Sep; 6(9):e2331919. PubMed ID: 37676662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Position statement on the hormonal management of adult transgender and gender diverse individuals.
    Cheung AS; Wynne K; Erasmus J; Murray S; Zajac JD
    Med J Aust; 2019 Aug; 211(3):127-133. PubMed ID: 31271465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.
    Chantrapanichkul P; Stevenson MO; Suppakitjanusant P; Goodman M; Tangpricha V
    Endocr Pract; 2021 Jan; 27(1):27-33. PubMed ID: 33471729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological and Metabolic Characteristics of a Cohort of Transgender and Gender-Diverse Youth in the United States.
    Millington K; Schulmeister C; Finlayson C; Grabert R; Olson-Kennedy J; Garofalo R; Rosenthal SM; Chan YM
    J Adolesc Health; 2020 Sep; 67(3):376-383. PubMed ID: 32417098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron.
    Eitel KB; Hodax JK; DiVall S; Kidd KM; Salehi P; Sequeira GM
    J Adolesc Health; 2023 Feb; 72(2):307-311. PubMed ID: 36404242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected vs. perceived effects of gender-affirming hormone therapy among transmasculine adolescents.
    Taillefer V; Kelley J; Marsolais S; Chiniara L; Chadi N
    J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1072-1078. PubMed ID: 37747085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes Following Acute Residential Psychiatric Treatment in Transgender and Gender Diverse Adolescents.
    Silveri MM; Schuttenberg EM; Schmandt K; Stein ER; Rieselbach MM; Sternberg A; Cohen-Gilbert JE; Katz-Wise SL; Blackford JU; Potter AS; Potter MP; Sarvey DB; McWhinnie CM; Feinberg JE; Boger KD
    JAMA Netw Open; 2021 Jun; 4(6):e2113637. PubMed ID: 34152417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional ovarian reserve in transgender men receiving testosterone therapy: evidence for preserved anti-Müllerian hormone and antral follicle count under prolonged treatment.
    Yaish I; Tordjman K; Amir H; Malinger G; Salemnick Y; Shefer G; Serebro M; Azem F; Golani N; Sofer Y; Stern N; Greenman Y
    Hum Reprod; 2021 Sep; 36(10):2753-2760. PubMed ID: 34411251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of gender-affirming hormone treatment on serum creatinine in transgender and gender-diverse youth: implications for estimating GFR.
    Millington K; Barrera E; Daga A; Mann N; Olson-Kennedy J; Garofalo R; Rosenthal SM; Chan YM
    Pediatr Nephrol; 2022 Sep; 37(9):2141-2150. PubMed ID: 35083530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.